IN THIS ISSUE
Managing Editor’s Memo
Frank Diamond
Legislation & Regulation
Richard Mark Kirkner
The House has passed legislation that the AMA and others endorse. But the sense that there is a malpractice crisis has ebbed and Senate action is unlikely.
Medication Management
Thomas Reinke
Varying treatment strategies for a highly variable disease have given the new drug an opening—and, besides, it does OK when it comes to QALYs.
Tomorrow's Medicine
Thomas Morrow and Managed Care editors
FDA approval of the CAR T-cell therapy for leukemia could usher in an era of genetically engineered, individually tailored immunotherapies. But tap those brakes. Long-term results are in short supply—and there’s that $475,000 price tag.
News & Commentary